Comparative validation of the SP6 antibody to Ki67 in breast cancer

Journal of Clinical Pathology

Volumn 63, Issue 9, 2010, Pages 800-804

  Zabaglo, Lila ^a,b   Salter, Janine ^a,b   Anderson, Helen ^a,b   Quinn, Emma ^a   Hills, Margaret ^a   Detre, Simone ^a   A'Hern, Roger ^c   Dowsett, Mitch ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b Breakthrough Breast Cancer Research Centre   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FORMALDEHYDE; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MIB1; MONOCLONAL ANTIBODY SP6; UNCLASSIFIED DRUG;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; FORMALDEHYDE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; KI-67 ANTIGEN; PARAFFIN EMBEDDING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77956892036     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.077578     Document Type: Article

References (32)

1. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterisation of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
2. Spyratos F, Ferrero-Pous M, Trassard M, et al. Correlation between MIB-1 and other proliferation markers: Clinical implications of the MIB-1 cutoff value. Cancer 2002;94:2151-9.
3. Ellis PA, Makris A, Burton SA, et al. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Br J Cancer 1996;73:640-3.
4. Thor AD, Liu S, Moore DH, et al. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol 1999;17:470-7. (Pubitemid 29075230)
5. Moriki T, Takahashi T, Kataoka H, et al. Proliferation marker MIB-1 correlates well with proliferative activity evaluated by BrdU in breast cancer: An immunohistochemical study including correlation with PCNA, p53, c-erbB-2 and estrogen receptor status. Pathol Int 1996;46:953-61.
6. Sasaki K, Matsumura K, Tsuji T, et al. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer 1988;62:989-93.
7. Sasaki K, Matsumura K, Murakami T, et al. Measurement of bromodeoxyuridine labeling index, Ki-67 score and Ag-NOR count in breast carcinomas. Comparison with DNA ploidy. Oncology 1992;49:147-53.
8. van Diest PJ, van der Wall E, Baak JPA. Prognostic value of proliferation in invasive breast cancer: A review. J Clin Pathol 2004;57:675-81.
9. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23:7212-20.
10. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007;96:1504-13.
11. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65. (Pubitemid 46606270)
12. Cuzick J, Dowsett M, Wale C, et al. Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrance score - results from TransATAC [abstract]. Cancer Res 2009;69(Suppl):503s.
13. Clarke RB, Laidlaw IJ, Jones LJ, et al. Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 1993;67:606-11.
14. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s-8s.
15. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6523-31.
16. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8.
17. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 2007;99:167-70.
18. Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000;89:2145-52.
19. Archer CD, Parton M, Smith IE, et al. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003;89:1035-41.
20. Jones RL, Salter J, A'Hern R, et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2009;116:53-68.
21. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63. (Pubitemid 23013251)
22. Wong SC, Chan JK, Lo ES, et al. The contribution of bifunctional SkipDewax pretreatment solution, rabbit monoclonal antibodies, and polymer detection systems in immunohistochemistry. Arch Pathol Lab Med 2007;131:1047-55.
23. Niu G, Sun X, Cao Q, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res 2010;16:2095-105.
24. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.
25. Dowsett M. Biomarker investigations from the ATAC trial: the role of TA01. Br Cancer Res Treat 2004;87(Suppl 1):S11-18.
26. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007;25:3816-22.
27. Hirokawa M, Carney JA. Cell membrane and cytoplasmic staining for MIB-1 in hyalinizing trabecular adenoma of the thyroid gland. Am J Surg Pathol 2000;24:575-8. (Pubitemid 30180752)
28. Hattori H. Sclerosing haemangioma of the lung is positive for MIB-1 in cell membrane and cytoplasmic staining pattern. Histopathology 2002;40:291-3.
29. Tashiro T, Hirokawa M, Harada H, et al. Cell membrane expression of MIB-1 in salivary gland pleomorphic adenoma. Histopathology 2002;41:559-61. (Pubitemid 36693603)
30. Leonardo E, Volante M, Barbareschi M, et al. Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl Immunohistochem Mol Morphol 2007;15:220-3.
31. Faratian D, Munro A, Twelves C, et al. Membranous and cytoplasmic staining of Ki67 is associated with HER2 and ER status in invasive breast carcinoma. Histopathology 2009;54:254-7.
32. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92.